Cidara Administers Initial Doses to Participants in Phase 3 ANCHOR Trial of CD388 for High-Risk Flu Patients

Phase 3 Trial Announcement: Cidara Therapeutics has initiated a Phase 3 trial for its drug candidate CD388, aimed at evaluating its safety and efficacy in high-risk populations for influenza complications, with a target enrollment of 6,000 subjects.

Drug Details and FDA Designation: CD388 is a long-acting antiviral drug that combines zanamivir with a human antibody fragment, and it has received Fast Track Designation from the FDA, positioning it as a potential alternative for those who do not respond to vaccines.